Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibemethine SCHEMBL276863 | 0.79 | ALDH1A1 (0.70) | PYCR1LMNATSHRUSP2CYP3A4 | |
| Dibemethine SCHEMBL10542007 | 0.79 | ALDH1A1 (0.70) | PYCR1LMNATSHRUSP2CYP3A4 | |
| Pargyline SCHEMBL18036659 | 0.79 | PYCR1 (1.00) | PYCR1LMNATSHRUSP2CYP3A4 | |
| Pargyline SCHEMBL2045 | 0.79 | PYCR1 (1.00) | PYCR1LMNATSHRUSP2CYP3A4 | |
| SCHEMBL2584302 | 0.79 | PYCR1 (0.66) | PYCR1LMNATSHRUSP2CYP3A4 | |
| SCHEMBL10684904 | 0.79 | PYCR1 (0.66) | PYCR1LMNATSHRUSP2CYP3A4 | |
| SCHEMBL7737898 | 0.78 | CHRNB2 (0.67) | PYCR1LMNATSHRUSP2CYP3A4 | |
| Pargyline SCHEMBL7363311 | 0.78 | PYCR1 (0.96) | PYCR1LMNATSHRUSP2CYP3A4 | |
| SCHEMBL14022799 | 0.78 | PYCR1 (0.68) | PYCR1LMNATSHRUSP2CYP3A4 | |
| Pargyline SCHEMBL121111 | 0.78 | LMNA (1.00) | PYCR1LMNATSHRUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736514-B1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-10-18 | — | — | EP | disclosed |
| US-8912200-B2 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-16 | — | — | US | disclosed |
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-10 | — | — | US | disclosed |
| EP-2736514-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014039-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | JAK2, JAK1, SRC | PYCR1 943/4885LMNA 4125/4885TSHR 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.